Shanghai Laishi Blood Products Co., Ltd. (the "Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without any false records, misleading statements, or significant omissions.
Special Reminder:
- Shanghai Laishi Blood Products Co., Ltd. ("Shanghai Laishi", "Company") has completed the cancellation of repurchased shares. A total of 45,311,952 shares were canceled, reducing the total number of shares from 6,637,984,837 to 6,592,672,885. Consequently, the voting rights proportion of the controlling shareholder, Haiyingkang (Qingdao) Medical Technology Co., Ltd. ("Haiyingkang"), increased passively from 29.90% to 30.10%.
- The number of shares held by the controlling shareholder (and the number of shares with voting rights) has not changed, and this change in equity will not lead to a change in the controlling shareholder or actual controller of the Company.
- According to the "Measures for the Administration of Acquisitions of Listed Companies," "Rules for the Repurchase of Shares by Listed Companies," and "Self-Regulatory Guidelines No. 9 for Listed Companies on the Shenzhen Stock Exchange - Repurchase of Shares," this change in equity qualifies for exemption from making a tender offer.